Clinical Trial: Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma
Brief Summary: Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.
Detailed Summary:
Sponsor: University Hospital Carl Gustav Carus
Current Primary Outcome: Specific T-cell proliferation/cytokine secretion
Original Primary Outcome: Same as current
Current Secondary Outcome:
- number of T cells [ Time Frame: pre and post vaccination ]
- monoclonal protein [ Time Frame: pre and post vaccination ]
- plasmacells in bone marrow [ Time Frame: pre and post vaccination ]
- vital signs [ Time Frame: pre and post vaccination ]
Original Secondary Outcome: Same as current
Information By: University Hospital Carl Gustav Carus
Dates:
Date Received: October 1, 2009
Date Started: March 2002
Date Completion:
Last Updated: October 1, 2009
Last Verified: October 2009
